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Abstract 
Background: Scutellarin, an anti‑inflammatory agent, effectively suppressed microglia activation in rats with middle 
cerebral artery occlusion (MCAO). Robust microglia activation, acute in onset, was followed by astrogliosis. This study 
was aimed to determine if scutellarin would also affect the reactive astrocytes that play an important role in tissue 
repair. Expression of GFAP and Notch‑1 and its members: Notch receptor intracellular domain (NICD), and transcrip‑
tion factor hairy and enhancer of split‑1 (HES‑1), together with nestin and proinflammatory mediators was assessed 
by immunofluorescence staining in TNC1 astrocytes treated, respectively, with BV‑2 conditioned medium (CM) and 
CM + lipopolysaccharide (LPS) (CM + L) serving as the controls, and conditioned medium derived from LPS‑activated 
BV‑2 cells pretreated with scutellarin (CM + SL). Study of the above biomarkers was then extended to reactive astro‑
cytes in scutellarin injected MCAO rats.
Results: TNC1 astrocytes remained relatively unreactive in terms of expression of different biomarkers to direct 
scutellarin treatment when compared with the control cells. In comparison to cells in the control medium (CM, 
CM + L), they responded vigorously to CM + SL as evidenced by the enhanced protein expression of GFAP, Notch‑1, 
NICD and HES‑1 coupled with that of nestin, TNF‑α, IL‑1β, and iNOS by Western and immunofluorescence analysis. 
Electron microscopy showed marked hypertrophy and cell expansion of TNC1 astrocytes bearing many filamentous 
processes indicative of enhanced astrocyte reaction when treated with CM + SL. In MCAO rats, scutellarin also aug‑
mented the expression of the above markers in reactive astrocytes; moreover, astrocytes were evidently hypertrophic.
Conclusions: The results suggest that scutellarin regulates astrogliosis; more importantly, it is microglia‑mediated as 
demonstrated in vitro. Increased expression of Notch signaling in synchrony with nestin may be linked to proliferation 
and “de‑differentiation” of reactive astrocytes; the significance of enhanced TNF‑α, IL‑1β and iNOS expression in reac‑
tive astrocytes by scutellarin may be neuroprotective but this remains speculative.
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Background
Scutellarin (4,5,6-trihydroxyflavone-7-glucuronide) is the 
major active component extracted from Erigeron brevis-
capus. It is a Chinese herbal compound endowed with 
antioxidant and anti-inflammation properties [1–4]. In 
the brain, scutellarin has been shown to decrease micro-
glia inflammatory response [4]. In addition to its anti-
oxidant and anti-inflammatory properties, scutellarin 
has been demonstrated to have anti-apoptotic proper-
ties in animal models of ischemic stroke [3]. We reported 
recently that scutellarin effectively suppressed produc-
tion of proinflammatory mediators in activated microglia 
in experimentally induced cerebral ischemia following 
middle cerebral artery occlusion (MCAO) in the adult 
rats and in BV-2 microglia in  vitro [5, 6]. It was shown 
that scutellarin decreased the production of proinflam-
matory cytokines including TNF-α and IL-1β and reac-
tive oxygen species (ROS) by activated microglia whose 
robust reaction featured prominently in the acute phase 
of cerebral ischemia. All this has pointed to the therapeu-
tic potential of scutellarin and its clinical use for amelio-
ration of microglia-mediated neuroinflammation.
While activated microglia evidently preponderated 
in the ischemic cerebral tissue in the early phase of 
MCAO [5, 6], massive astrocytes soon accumulated the 
infarcted areas. Indeed cerebral ischemia leads to wide-
spread progressive alterations in astrocytes, including 
cell hypertrophy, upregulation of intermediate filaments 
and increase in cell proliferation, commonly referred 
to as reactive astrogliosis [7–11]. The close spatial rela-
tion between activated microglia and reactive astrocytes 
in the ischemic area invites speculation that both glial 
cells might work in concert through cellular interaction 
or communication in the ensuing healing process. The 
functional relationship between activated microglia and 
reactive astrocytes, however, has remained to be fully 
explored. In consideration of scutellarin as a potential 
therapeutic agent, it is therefore desirable to determine if 
it would also act on astrocytes as for activated microglia, 
and if so, the mode of its action on astrocytes.
This study was therefore aimed to determine whether 
scutellarin would exert its effects on astrocytes that 
are closely associated with activated microglia. In 
the latter, we have reported that expression of pro-
inflammatory mediators and Notch-1 pathway and its 
members was significantly suppressed by scutellarin. 
It is relevant therefore to ascertain if these biomarkers 
strongly expressed in reactive astrocytes would also be 
affected. Secondly, if indeed scutellarin were able to affect 
or regulate the astrocyte reaction, a compelling question 
would be whether it would directly act on astrocytes, or 
indirectly such as via activated microglia. In the latter, the 
notion took into consideration of the reactive response of 
microglia and astrocytes in temporal sequence [12, 13] 
in cerebral ischemia, in which acute microglial activation 
appears to precede that of astrocyte reaction; further-
more, both glial cells are spatially related. We report here 
that scutellarin could enhance the expression of GFAP, 
nestin, Notch-1 signaling and its members in TNC1 
astrocytes as well as in reactive astrocytes in MCAO 
rats. More strikingly, scutellarin was found to amplify the 
expression of above-named biomarkers along with proin-
flammatory mediators, a process that is mediated by acti-
vated microglia as demonstrated in vitro.
Results
TNC1 viability assay with scutellarin
TNC1 astrocyte cell line instead of primary cultured 
astrocytes was used for this study to ensure that we 
obtained enough cells for adequate amounts of pro-
tein for Western blot analysis. The cytotoxicity data was 
obtained by the MTS assay for the effect of scutellarin 
on TNC1 cells. Scutellarin (in the range of 0.2–2.0 mM) 
did not result in any significant cell death (Fig. 1a). In this 
study, we have used scutellarin at 0.54  mM for all sub-
sequent analysis. This dosage was used for treatment 
of BV-2 cells also in our previous studies in which dose 
dependent assay had earlier been done [5, 6].
Scutellarin does not exert a direct effect on TNC1
To determine if scutellarin would exert a direct effect 
on TNC1, it was added directly into the medium with 
TNC1. By phase contrast microscopy, the external mor-
phology of TNC1 astrocytes incubated in the basic 
medium + 0.54 mM scutellarin (BM + S) appeared com-
parable to that in the control cells in the basic medium 
(BM). Furthermore, TNF-α (Fig. 1b: compared B1–3 with 
A1–3) and iNOS (Additional file 1a) immunofluorescence 
in BM  +  S remained relatively unaltered as compared 
with the control cells incubated in BM. This indicates that 
scutellarin does not stimulate TNC1 directly.
Lipopolysaccharide (LPS) does not exert a direct effect 
on TNC1
By RT-PCR, TNF-α (Fig.  1c) and iNOS (Additional 
file  1b) mRNA expression levels in TNC1 astrocytes 
incubated in the basic medium (BM), BM  +  LPS 
(BM  +  L) and BV-2 conditioned medium (CM) were 
negligible. Remarkably, the mRNA expression lev-
els were drastically increased by several hundred folds 
when treated with LPS-stimulated BV-2 conditioned 
medium (CM  +  L) (Fig.  1c; Additional file  1b). This 
shows that TNC1 activation was only mildly elicited 
and directly by LPS; instead, its vigorous activation is 
mediated by activated microglia. TNF-α, IL-1β and 
iNOS were used as markers for reactive astrocytes along 
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with GFAP because these proinflammatory mediators 
have been reported to be highly expressed in activated 
astrocytes [14, 15].
TNC1 activation is mediated by activated microglia
Microglia-mediated activation of TNC1 astrocytes was 
further evidenced by the drastic increase in GFAP (Fig. 1d: 
C1–C3), TNF-α (Fig.  1d: D1–D3) and iNOS (Additional 
file  1c: C1–C3) immunofluorescence in cells incubated 
in CM  +  L compared with cells incubated in BM and 
BM  +  L groups. Furthermore, TNC1 cells treated with 
CM + L appeared evidently hypertrophic (Fig. 1d: C3, D3).
Scutellarin upregulates GFAP, Notch‑1, NICD, HES 
and nestin expression in TNC1 via BV‑2‑conditioned 
medium
GFAP was moderately expressed in TNC1 incubated in 
CM (a1, Fig.  2); it was enhanced in TNC1 treated with 
CM  +  L (a2, Fig.  2). Notch-1, NICD, HES and nestin 
expression was hardly detected in CM group (Fig.  2B1, 
C1, D1, E1), but was enhanced in CM +  L (b2, c2, d2, 
e2). Remarkably, upon pretreatment with scutellarin in 
CM +  SL for 24  h, expression of all markers was dras-
tically increased being more pronounced for NICD 
(Fig. 2C3) and nestin (Fig. 2E3).
Fig. 1 Cell viability assay of TNC1 astrocytes (a): scutellarin (in the range of 0.2–2.0 mM) incubated for different duration did not result in any 
significant cell death. Treatment of TNC1 with scutellarin (b): scutellarin at 0.54 mM did not elicit a noticeable reaction in TNC1 whose GFAP/TNF‑α 
(B1–3) expression remained comparable to cells in the control in basic medium (BM) (A1–3). BM + S, basic medium + scutellarin. Microglia mediate 
TNC1 astrocyte reaction (c): TNF‑α mRNA expression in TNC1 astrocytes remained relatively unchanged at all time‑points following treatment with 
BM, BM + L and BV‑2 conditioned medium (CM). However, in TNC1 incubated CM + L for various time points, TNC1 showed a remarkable increase 
in TNF‑α peaking at 24 h. Confocal images in d showing GFAP (C1–3), and TNF‑α (D1–3) expression in TNC1 astrocytes incubated with different 
medium for 24 h. Compared with cells incubated in BM and BM + LPS (BM + L), TNC1 astrocytes incubated with LPS‑stimulated BV‑2 cell condi‑
tioned medium (CM + L) (C3, D3) are hypertrophic and exhibit a marked increase in GFAP and TNF‑α immunofluorescence. Scale bars 20 μm
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Fig. 2 Scutellarin enhanced GFAP (A1–A3), Notch‑1 (B1–B3), NICD (C1–C3), HES‑1 (D1–D3), nestin (E1–E3) and TNF‑α (A1–3) expression in TNC1 
via BV‑2‑conditioned medium. Moderate GFAP expression was detected in TNC1 incubated in CM; also, Notch‑1, NICD, HES‑1, nestin and TNF‑α (B1, 
C1, D1, E1, F1) was weakly expressed. The expression however was enhanced in CM + L (B2, C2, D2, E2, F2). Upon treatment with CM + SL for 
24 h, expression of all markers was drastically increased being more pronounced for NICD (C3) and nestin (E3). Note TNC1 astrocytes project long 
cytoplasmic processes with expansions (A3, D3, F3). Scale bars 20 μm
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Scutellarin upregulates TNF‑α, IL‑1β and iNOS expression 
in TNC1 via BV‑2‑conditioned medium
In TNC1 incubated in CM, the cells exhibited moderate 
TNF-α expression (Fig.  2F1) which was augmented in 
CM + L (F2). When treated with CM + SL, the expres-
sion was further enhanced (Fig.  2F3). A similar pattern 
in expression changes was observed for IL-1β and iNOS 
(Additional file  2). A striking morphological change in 
TNC1 astrocytes treated with CM +  SL was the exten-
sion of long cytoplasmic processes emanated from the 
hypertrophic cell body (Fig. 2F3; Additional file 2B3). By 
contrast, the cells in CM appeared more rounded, and 
those in CM + L showed only a few short processes.
Western blot analysis of GFAP, Notch‑1, NICD, HES‑1, TNF‑α, 
IL‑1β and iNOS in TNC1 in different treatments
The expression level of GFAP (51  kDa), Notch-1 
(120 kDa), NICD (80 kDa), and HES-1 (35 kDa) was sig-
nificantly increased after treatment with CM +  L when 
compared with the control in CM (Fig. 3a); likewise, the 
expression of TNF-α, IL-1β and iNOS was significantly 
increased (Fig. 3b). In CM + SL treated TNC1, the expres-
sion levels of the above proteins were further elevated as 
compared with that of CM + L treated cells. Expression 
changes of the respective proteins are indicated against 
the corresponding bar graphs (Fig. 3). The optical density 
values (mean ± SD) of each marker are given in Table 1.
Electron microscopy
By scanning electronic microscopy, most TNC1 astro-
cytes in CM group were oblong; on closer examina-
tion, the surface projected some filamentous processes 
(Fig.  4a). In CM  +  L group, the cells became hyper-
trophic bearing long extending processes (Fig. 4b) when 
compared with cells in the CM group; the processes in 
some cells were expanded (Fig. 4b). Most of the cells in 
CM  +  SL group were grossly hypertrophic (Fig.  4c); 
large numbers of filamentous processes projected from 
the cell surface and appeared to intertwine with those 
emanated from the adjacent cells (Fig.  4c). Most strik-
ingly, TNC1 astrocytes in CM  +  SL spread out exten-
sively and thinly giving them a “squamous” appearance. 
In transmission electron microscopy, TNC1 astrocytes in 
all three groups showed a round nucleus bearing one to 
three conspicuous nucleoli (Fig.  4d). The copious cyto-
plasm in CM + SL group as compared with the other two 
groups was filled with polyribosomes and the usual cell 
organelles (Fig. 4d). Compared with other groups, cells in 
CM + SL had a larger cell profile. Many long filamentous 
processes projected from the cell surface as observed by 
scanning electron microscopy.
Morphological evidence of interaction between activated 
microglia and reactive astrocytes
In rats subjected to MCAO, a large infarcted area was 
observed in the ipsilateral cerebrum at early time-points. 
By immunofluorescence labeling, the epicenter of the 
infarcted area at 3 and 7 days after MCAO was occupied 
by massive activated microglia labeled by lectin (Fig. 5). 
On closer examination, the lectin labeled activated 
microglia were mostly round with some cells emitted 
short cytoplasmic processes (Fig.  5). At the border area 
with the non-lesion cortex or adjacent to it (penumbral 
area), activated microglia were admixed with GFAP posi-
tive astrocytes that appeared hypertrophic with long pro-
jecting and broad processes (Fig. 5); in some areas, both 
glial cell types were closely associated or intermingled. In 
non-lesion area, microglia and astrocytes appeared rela-
tively normal both bearing fine processes; furthermore, 
their close spatial relation as observed in the lesion zone 
was not evident (Fig. 5).
Scutellarin enhanced astrocyte reaction in ischemic cortex
By immunofluorescence microscopy, robust astro-
cyte reaction was observed in the penumbral region in 
ischemic cerebral cortex, notably at 7 and 14  days after 
MCAO. MCAO induced astrocyte reaction was evi-
denced by the enhanced GFAP labeling coupled with 
increased expression of Notch-1 (Fig. 6) and its members, 
NICD (Fig. 7) and HES-1 (Fig. 8). A striking feature after 
MCAO was the induced expression of nestin in GFAP 
positive astrocytes (Fig. 9). Expression of TNF-α (Fig. 10), 
IL-1β (Additional file 3) and iNOS (Additional file 4) was 
concomitantly augmented.
In MCAO rats given scutellarin injections, astrocytic 
reaction as manifested by the immunofluorescence of 
the above-mentioned markers was further enhanced. 
Astrocytes were grossly hypertrophic in compari-
son with the matching MCAO control rats without 
scutellarin or sham group. Scutellarin further elevated 
the MCAO-induced expression of Notch-1 (Fig.  6), 
NICD (Fig.  7), HES-1 (Fig.  8) and nestin (Fig.  9). In 
parallel to this, expression TNF-α (Fig.  10), IL-1β 
(Additional file 3) and iNOS (Additional file 4) immu-
nofluorescence in the reactive astrocytes also became 
more pronounced. The enhanced increase for the above 
biomarkers by scutellarin was progressive when com-
pared with counterpart cells in the MCAO and sham 
group being most pronounced at 7  days and was sus-
tained till 14 days; thereafter, the expression appeared 
to diminish but remained to be more intense when 
compared with cells at the corresponding time-points 
at 21 days (Additional file 5).
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Scutellarin not only accentuated the immunofluo-
rescence of the various markers in reactive astrocytes, 
but also induced the changes of their phenotype. 
Thus, in MCAO rats given scutellarin treatment, the 
cells were evidently enlarged bearing dilated processes 
notably at 7 and 14 days (Figs. 6, 7, 8, 9, 10, Additional 
files 3, 4). GFAP labeled hypertrophic astrocytes often 
extended their long processes between activated 
microglia or encircled the outer walls of the blood 
vessels (Fig. 5).
Fig. 3 Protein expression of GFAP, Notch‑1, NICD, HES‑1, TNF‑α, IL‑1β and iNOS in TNC1 following different treatments. a Expression levels of GFAP, 
Notch‑1, NICD, and HES‑1 were significantly increased after treatment with CM + L when compared with the control in CM; likewise, the expression 
of TNF‑α, IL‑1β and iNOS was significantly increased. b In CM + SL treated TNC1, the expression levels of the above markers were further elevated 
as compared with that of CM + L treated cells. Bar graphs represent expression changes of the respective markers. Significant differences in protein 
levels are expressed as *#P < 0.05. The values represent the mean ± SD in triplicate. #CM + L vs CM, *CM + SL vs CM + L
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Discussion
Direct effects of scutellarin on microglia and astrocytes
We reported recently that scutellarin could suppress 
NFkB and Notch signaling in activated microglia in their 
production of proinflammatory mediators in MCAO rats 
as well as in BV-2 cells [5, 6].This was sequel to our ear-
lier demonstration that Notch-1 expression in activated 
microglia could transactivate NFkB that is linked to pro-
duction of proinflammatory mediators [16–18]. In light of 
this, it was therefore concluded that scutellarin is a poten-
tial therapeutic agent that can attenuate microglia-medi-
ated neuroinflammation in ischemic/hypoxic brain injury. 
It is well documented that associated with the microglia 
activation in ischemic injury, astrogliosis also featured 
prominently [19, 20]. Indeed, following diverse brain 
injuries, astrocytes are activated and described as reac-
tive astrocytes [21–23]. Reactive astrocytes are known to 
undergo proliferation and are involved in different func-
tions such as scar formation and tissue repair among oth-
ers [19, 24]. Scutellarin could reduce the infarct area in 
rats with MCAO [5] indicating that it can promote tissue 
repair in ischemic injury and, hence, exert its effects on 
reactive astrocytes which play a pivotal role in this pro-
cess. The purpose of this study was to ascertain if scutel-
larin would act on astrocytes, and if so, to determine its 
mode of action. For this, we first investigated the effect 
of scutellarin on TNC1 astrocytes in  vitro. As opposed 
to BV-2 cells, direct application of scutellarin to TNC1 
did not elicit an obvious increase in GFAP expression, a 
specific marker for astrocytes; moreover, neither TNF-α 
nor iNOS expression was noticeably altered. It stands to 
reason therefore that scutellarin does not act directly, if 
at all, on astrocytes. It was then surmised that scutellarin 
might act through intermediary cells. A putative candi-
date for this would be the microglia whose activation in 
the ischemic injury is acute in onset [25] and invariably 
precedes that of astrocytes; furthermore, activated micro-
glia and reactive astrocytes at the injury site are in close 
proximity as is evident in the present MCAO model sug-
gesting the possibility of their functional interaction.
Microglia mediate astrocyte reaction
In consideration of a possible interaction between 
activated microglia and astrocytes, TNC1 astrocytes 
were first exposed to basic medium (BM), or basic 
medium  +  LPS (BM  +  L). Interestingly, GFAP, TNF-α 
and iNOS expression between the two TNC1 groups was 
moderate and comparable. This suggests that direct LPS 
treatment did not evoke a noticeable response in TNC1 
astrocytes. Against this however was the report that 
LPS could activate the primary astrocytes bearing TLR4 
[26]. The discrepancy in results may be attributed to dif-
ferent cell models used. Remarkably, when TNC1 astro-
cytes were exposed to conditioned medium derived from 
LPS-stimulated BV-2 cells (CM + L), a vigorous response 
was observed as manifested by the marked increased in 
GFAP, TNF-α and iNOS expression. As a corollary, it is 
suggested that the drastic TNC1 astrocyte reaction is 
mediated by activated microglia.
Scutellarin amplifies microglia‑mediated astrocyte 
reaction
The present results have shown that scutellarin is capable 
of amplifying the astrocyte reaction. This notion lends its 
support from the fact that GFAP, Notch-1, NICD, HES-
1, nestin expression along with that of TNF-α, IL-1β 
and iNOS was noticeably increased in TNC1 astrocytes 
exposed to CM  +  SL, when compared with cells incu-
bated in CM + L. By Western blot, the increase was in the 
range of 10–30 % of the expression levels across the vari-
ous proteins. A similar increase in expression occurred 
in reactive astrocytes in MCAO rats given scutella-
rin treatment. In this, the reactive astrocytes exhibited 
more intense immunofluorescence of the above markers 
compared with MCAO rats not treated with the drug. 
Microglia-mediated astrocyte reaction is also evident by 
an apparent hypertrophy of astrocytes bearing long fila-
mentous processes and expansion of cells as revealed by 
electron microscopy. The functional significance for the 
phenotypic change is uncertain but it may promote com-
munication between reactive astrocytes via the inter-
twined filamentous in tissue repair. In MCAO, the long 
extending processes of reactive astrocytes were observed 
to intercalate between activated microglia. The close 
spatial relation between activated microglia and reac-
tive astrocytes in the complex environment in ischemic 
tissue may facilitate a paracrine function. Indeed, it was 
reported that activated microglia through production 
Table 1 Optical density values of each protein marker (mean ± SD)
#* P < 0.05; # CM + L vs CM, * CM + SL vs CM + L
Notch‑1 NICD HES‑1 TNF‑α IL‑1β iNOS GFAP
CM 0.68 ± 0.10 0.42 ± 0.04 0.48 ± 0.07 0.65 ± 0.03 0.43 ± 0.08 0.78 ± 0.12 0.96 ± 0.04
CM + L 0.83 ± 0.03# 0.66 ± 0.06# 0.58 ± 0.02# 1.16 ± 0.11# 0.93 ± 0.16# 1.09 ± 0.26# 1.07 ± 0.04#
CM + SL 0.92 ± 0.02 0.80 ± 0.09* 0.65 ± 0.01* 1.36 ± 0.19* 1.13 ± 0.11* 1.55 ± 0.16* 1.18 ± 0.09*
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of MCSF could stimulate astrocytes in their production 
of proinflammatory cytokines [15] suggesting the func-
tional relation or communication between two glial cell 
types. Furthermore, it has been reported that the com-
munication pathways among microglia, astrocytes and 
neurons are responsible for neuroprotection [27]. Such 
communication may be mediated by microglia ATP via 
P2Y1 receptor on astrocyte which resulted in production 
of IL-6 that provides neuroprotection. Crosstalk between 
macrophages and astrocytes affecting the proliferation, 
Fig. 4 Scanning electron microscopy of TNC1 astrocytes in CM (A1–2), CM + SL (B1–2) and CM + SL (C1–2) groups. Note the drastic transfor‑
mation of TNC1 from oblong outline (CM, A1–2) to “squamous” appearance in the CM + SL (C1–2) whose cell surface exhibit a large number of 
filamentous processes (arrows). By transmission electron microscopy (D1–3), TNC1 astrocytes in CM + SL are evidently enlarged (D3) as compared 
with CM (D1) and CM + L (D2) groups; moreover, the cells contain a larger amount of cytoplasm rich in polyribosomes and usual organelles
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reactive phenotype and inflammatory response, suggest-
ing a role during reactive gliosis following spinal cord 
injury has recently been reported [28].
Scutellarin enhances GFAP, Notch‑1 pathway and nestin 
expression in reactive astrocytes
Contrary to its suppression of microglia activation in 
MCAO model and BV-2 cells, we show here that scutella-
rin instead promotes the astrocyte reaction as shown by 
the enhanced expression of Notch-1, NICD and HES-1. 
Additionally, scutellarin expanded the expression of nes-
tin in virtually every reactive astrocyte both in vitro and 
in  vivo. Reactive astrogliosis is reported to be involved 
in tissue repair or scar formation. It is conceivable that 
increase in hypertrophic astrocytic processes with 
enhanced GFAP which constitutes the cytoskeleton or 
intermediate filaments would facilitate such a function. 
Furthermore, vascular profiles of varying sizes in the 
penumbral region appeared to be fully invested by astro-
cytic end-feet suggesting that the integrity of the blood–
brain barrier which would have been compromised in 
ischemia is being restored.
Nestin is a marker of neural stem cells and neu-
ral progenitor cells, and its expression is observed in a 
Fig. 5 Morphological evidence of interaction between activated microglia and reactive astrocytes. Figure showing ipsilateral ischemic cerebral 
cortex at 3 days after MCAO. The dotted line in A delineates approximately the border of the infarct epicenter which shows massive accumulation of 
activated microglia intermingled with reactive astrocytes. B1, B2 show lectin‑labeled activated microglia (green). They are obviously hypertrophic 
and are mostly rounded (B1) or emit short stout processes (B2). GFAP labeled reactive astrocytes (red) are also hypertrophic, and extend their long 
processes between the activated microglia; in some areas, they are closely associated (B1, B2). Astrocytic processes also surround the blood vessel 
(BV) in B1, B2. The close spatial relation between the activated microglia and reactive astrocytes is not evident away from the border (B3). B1–3 are 
enlarged view of area 1–3 in A. Scale bar in A: 100 μm; scale bar in B: 50 μm. DAPI, blue
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Fig. 6 Scutellarin enhanced Notch‑1expression in astrocytes after MCAO. Notch‑1 expression is negligible in astrocytes in the sham (A1–3). Its 
expression (red) was moderately induced by MCAO in GFAP positive astrocytes (green) at 7 (B1–3) and 14 days (D1–3). However, Notch‑1 expression 
was markedly increased in hypertrophic astrocytes in scutellarin treated MCAO rats (C1–3, E1–3) in comparison with the matching controls (B1–3, 
D1–3). Scale bars: 50 µm. DAPI‑blue
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Fig. 7 Scutellarin enhanced NICD expression in astrocytes after MCAO. NICD expression is absent in astrocytes in the sham (A1–3). Its expression 
(red) was moderately induced after MCAO in GFAP positive astrocytes (green) at 7 days (B1–3) but was diminished at 14 days (D1–3). However, 
NICD expression was markedly increased in hypertrophic astrocytes in scutellarin treated MCAO rats (C1–3, E1–3) in comparison to the matching 
control groups (B1–3, D1–3). Scale bars: 50 µm. DAPI‑blue
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Fig. 8 Scutellarin enhanced HES‑1 expression in astrocytes after MCAO. HES‑1 expression is undetected in astrocytes in the sham (A1–3). Its 
expression (red) was moderately induced after MCAO in GFAP positive astrocytes (green) at 7 days (B1–3) but was attenuated at 14 days (D1–3). 
However, HES‑1 expression was markedly increased in hypertrophic astrocytes in scutellarin treated MCAO rats at 7 (C1–3) and 14 days (E1–3) in 
comparison to the matching control groups (B1–3, D1–3). Scale bars: 50 µm. DAPI‑blue
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Fig. 9 Scutellarin enhanced nestin expression in astrocytes after MCAO. Nestin expression is undetected in astrocytes in the sham (A1–3). It (red) 
was moderately induced in GFAP positive astrocytes (green) in MCAO rats at 7 (B1–3) but declined at 14 days (D1–3). However, nestin expression 
was markedly increased in hypertrophic astrocytes in scutellarin treated MCAO rats at 7 (C1–3) and 14 days (E1–3) in comparison to the matching 
control groups (B1–3, D1–3). Scale bars: 50 µm. DAPI‑blue
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Fig. 10 Scutellarin enhanced TNF‑α expression in astrocytes after MCAO. TNF‑α expression (red) was absent in astrocytes in the sham (A1–3). It was 
induced in GFAP positive astrocytes (green) at 3 and 7 days (B1–3) after MCAO, but the expression subsided at 14 days (D1–3). In MCAO rats treated 
with scutellarin (C1–3, E1–3). TNF‑á expression in astrocytes was markedly enhanced being most pronounced at 7 days when compared with the 
matching MCAO control groups (B1–3, D1–3). Scale bars: 50 µm. DAPI‑blue
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subpopulation of reactive astrocytes [24, 29]. It is a class 
VI intermediate filament protein that was first described 
as a neural stem/progenitor cell marker [30]. Neuroepi-
thelial stem cells can differentiate into neurons, oligo-
dendrocytes, and astrocytes, and nestin has been shown 
to be down-regulated or to completely disappear during 
such differentiation. Here we showed that nestin which 
was hardly detected in TNC1 was induced in some cells 
in CM  +  L conditioned medium. In CM  +  SL treated 
cells, nestin expression was detected and markedly 
enhanced in all cells. Virtually all GFAP labeled reac-
tive astrocytes in scutellarin injected MCAO rats emit-
ted intense nestin immunofluorescence compared with 
the matching control at the corresponding time-points. 
The expression of nestin in reactive astrocytes suggests 
that some of them had “de-differentiated” and assumed a 
“stemness” property, but it remains to be determined if 
they might differentiate [31]. While reactive astrocytes 
appear to have greater plasticity than was previously 
realized [32], and may provide a source of multipotent 
cells or functional neurons for regenerative medicine, 
the signaling pathway(s) that govern the formation of 
injury-induced nestin positive reactive astrocytes hav-
ing the potential of neural stem cells remains uncer-
tain. Thus, the demonstration of Notch-1 signaling and 
its members both in vivo and in vitro in this study may 
provide a clue for the regulatory mechanism of nestin 
expression in reactive astrocytes. It is relevant therefore 
to note that proliferating reactive astrocytes are regu-
lated by Notch-1 in the peri-infarct area after stroke [23]. 
It has been reported that treatment of MCAO mice with 
DAPT, an inhibitor of γ secretase, decreases the number 
of olig2+ and nestin+ reactive astrocytes [33] alluding to 
the possibility that Notch-1 signaling in reactive astro-
cytes regulates nestin expression. The colocalization and 
concurrent upregulation of Notch-1 signaling and nestin 
in reactive astrocytes in the present results suggest that 
both may operate in synergy; but in the lack of experi-
mental evidence, this remains purely speculative. Other 
pathways or molecules such as miRNAs known to regu-
late astrogliosis [34–36], and that might be involved in 
microglia-mediated astrocyte reaction and modulated by 
scutellarin should be future scope of study.
Scutellarin promotes TNF‑α, IL‑1β and iNOS in reactive 
astrocytes
While scutellarin decreases the expression of proinflam-
matory mediators including TNF-α, IL-1β, iNOS and NO 
production in activated microglia, it conversely upregu-
lates their expression in reactive astrocytes. It is well 
documented that excess production of proinflammatory 
mediators from activated microglia is detrimental to neu-
rons [37]; on the other hand, their increased production 
in reactive astrocytes by scutellarin remains speculative. 
There is increasing agreement that TNF-α in  vitro and 
in  vivo may protect neurons against excitotoxic, oxida-
tive and ischemic injuries. It may be hypothesized that 
TNF-α is not potent to kill neurons by itself, but it may 
function synergistically with other cytokines and toxic 
agents such as NO, free radicals or glutamate [38]. Like-
wise, IL-1β can promote survival of retinal ganglion cells 
[39] and neurons [40]. Furthermore, it has been reported 
that nitric oxide could induce the expression of GFAP in 
reactive astrocytes which exhibit iNOS expression [41]. It 
has been reported that iNOS-derived NO can act as an 
endogenous antioxidant in traumatic brain injury sug-
gesting the neuroprotective role of iNOS [42]. Taken 
together, it is suggested that the increased expression of 
TNF-α, IL-1β and iNOS by scutellarin might not neces-
sary be neurotoxic, but can be neuroprotective. It may 
also be argued that the final result/amount of scutellarin-
regulated pro-inflammatory mediators would determine 
whether they are neurotoxic or neuroprotective but this 
remains debatable. From a speculative point of view, 
TNF-α, IL-1β and iNOS derived from reactive astrocytes 
might be beneficial instead of cytotoxic as those from 
activated microglia.
Conclusion
Scutellarin can regulate the expression of GFAP, Notch-1 
signaling, and nestin along with that of proinflammatory 
mediators in reactive astrocytes in ischemic injury. In 
vitro results showed that scutellarin did not exert a direct 
effect on astrocytes; rather, it acted through the interme-
diary activated microglia. Scutellarin acts primarily to 
amplify the microglia-mediated astrocyte reaction thus 
highlighting a functional “cross-talk” between activated 
microglia and reactive astrocytes. On the other hand, the 
specific molecules such as cytokines involved in this are 
uncertain. Notwithstanding, it is concluded that scutel-
larin is a potent agent that can facilitate the communica-
tion between activated microglia and reactive astrocytes 
in ischemic injury, an inter-glial cell mechanism that may 
be crucial to issue repair.
Methods
Cell culture and in vitro study
DI TNC1, type 1 phenotype of Rattus norvegicus astro-
cyte purchased from American Type Culture Collection 
(ATCC, USA, CRL-2005™) was maintained in 75  cm2 
culture flasks with completed medium composed of basic 
medium (Dulbecco’s Modified Eagle’s Medium, Sigma, 
St. Louis, MO, USA; Cat. No. 1152) and supplement 
with 10 % fetal bovine serum (FBS, HyClone, Logan, UT, 
USA). The cultures were incubated at 37 °C in a humidi-
fied incubator under 5 % CO2.
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BV-2 cells (a widely used murine microglial cell line) 
were maintained in our laboratory under the same con-
dition as for TNC1 for the production of conditioned 
medium.
Cell viability assay of TNC1 astrocytes
Cell viability was assessed by CellTiter 96  W Aque-
ous One Solution Cell Proliferation Assay kit (Promega, 
Fitchburg, WI, USA; Cat. No. G3580). To determine the 
cytotoxic effect of scutellarin on TNC1, cells were plated 
into 96-well microplates (104 cells/well) and cultured 
for 24  h. They were subjected to treatment of scutel-
larin (in the range of 0.2–2.0  mM) in each well con-
taining 100  μl of culture medium for 1  h in triplicates. 
Briefly, 20  μl of MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium, inner salt) reagent was added to each well (final 
concentration, 0.5 mg ml−1) and the plate was incubated 
for an additional 4 h. The optical density (OD) was then 
read at 490  nm using a microplate reader (GENIOS, 
Tecan, Switzerland). The assays were performed in 
triplicate.
Preparation and use of BV‑2 conditioned medium
At 24  h after BV-2 cell seeding, the medium was dis-
carded. Three different kinds of conditioned medium 
were prepared: BV-2 conditioned medium as con-
trol (CM): incubation of BV-2 cells was in 10  mL basic 
DMEM for 3  h; BV-2 conditioned medium +  lipopoly-
charride (LPS) (CM  +  L): BV-2 cells were incubated 
with 10 mL basic medium with 1 µg/ml of LPS for 3 h; 
BV-2 conditioned medium with scutellarin pretreat-
ment  +  LPS (CM  +  SL): for this, BV-2 cells were first 
incubated with 10 ml basic medium containing 0.54 mM 
of scutellarin for 1 h. This dosage was used based on the 
cell viability assay and the dose-dependency assay by us 
previously [5, 6]; the medium was then discarded and the 
cells were washed with PBS twice. Following this, 10 ml 
basic medium containing 1 µg/ml of LPS was added for 
another 3 h. All 3 conditioned media were collected and 
filtered through 0.22  μm syringe filters; they were then 
ready to use for treatment of TNC1 astrocytes.
TNC1 astrocytes and treatment with BV‑2 conditioned 
medium
TNC1 astrocytes were divided into control (CM), LPS-
induced (CM  +  L) and scutellarin  +  LPS (CM  +  SL) 
groups based on treatment with the respective condi-
tioned medium. TNC1 cells were seeded at a density of 
3.0 × 105 in 6-well plates and 5.0 × 104 in 24-well plates, 
incubated with a complete medium. After 24  h, the 
medium was discarded and the cells were incubated with 
2 ml (6-well plates) or 1 ml (24-well plates) of conditioned 
medium for 24 h. The cells were then harvested for pro-
tein extraction and RNA isolation (6-well plates) or 
immunofluorescence microscopy (24-well plates).
RNA isolation and real‑time RT‑PCR for validation of TNCI 
reaction
Total RNA from TNC1 astrocytes was extracted 
using miRNeasy Mini Kit (Qiagen, Germany, Cat. No. 
217004) according to the manufacturer’s instructions. 
After this, 1  μg of RNA from each sample was added 
to a total volume of 20  μl reaction mixture contain-
ing 0.5  μg of oligo (dT) primer (Promega, Madison, 
WI, USA; Cat. No. A3500), and 15U of AMV Reverse 
Transcriptase (Promega, Madison, WI, USA; Cat. No. 
M5314). The reaction was initiated by incubating the 
reaction mixture for 15  min at 42  °C, then heating at 
95  °C for 5  min, and stopped by incubating at 0–5  °C 
for 5  min. Aliquot (3  μl) of each of the diluted reverse 
transcription products (diluted by 1:5) was added to the 
10  μl reaction mixture containing 5  μl of GoTaq@qPCR 
Master Mix (Promega, Madison, WI, USA; Cat. No. 
A6001/2), 0.5  μM of each primer corresponding to 
TNF-α, iNOS and β-actin, to amplify the genes in ABi 
7900HT Fast PCR system (Applied Biosystems, USA). 
The primer sequences of TNF-α are forward: 5′-TATG 
GCTCAGGGTCCAACTC-3′ and reverse: 5′-CTCCC 
TTTGCAGAACTCAGG -3′, iNOS are forward: 5′- CT 
CACTGGGACAGCA CAGAA -3′ and reverse: 5′- GCT 
TGTCTCTGGGTCCTCTG-3′, β-actin are forward: 
5′-AGCCATGTACGTAGCCATCC-3′ and reverse: 
5′-GCTGTGGTGGTGAAGCTGTA-3′. After pre-incu-
bation at 95 °C for 15 min, the polymerase chain reaction 
(PCR) was performed as follows: 40 cycles of denatura-
tion at 94  °C for 15  s, annealing at 57  °C for 25  s, and 
elongation at 72 °C for 15 s.
Western blotting analysis for DI TNC1 astrocytes
After incubating with different media for 24  h, TNC1 
astrocytes of different groups (CM, CM  +  L and 
CM  +  SL) were treated with lysis buffer after rinsing 
twice with 1xPBS. Cell lysate was mechanically scrapped 
off and centrifuged at 14,000  rpm for 15  min and the 
supernatant was collected. Protein concentrations of 
TNC1 astrocytes were determined with a colorimet-
ric protein assay by protein assay kit (Bio-Rad, Hercu-
les, CA, USA; Cat. No. 500-0002). Protein samples were 
then heated with 6x protein loading buffer at 95  °C for 
5 min to denature the protein. Thirty μg of each protein 
sample was separated on sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS-PAGE) with 10  % 
gels, in a Mini-Protein II apparatus (Bio-Rad, CA, USA). 
Protein bands were electroblotted onto polyvinylindene 
difluoride (PVDF) membrane and blocked with non-fat 
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dried milk for 1 h. The membranes were incubated with 
TNF-α (rabbit polyclonal IgG 1:1500) (Sigma-Aldrich; 
Cat. No. T8300), IL-1β (rabbit polyclonal IgG 1:500) 
(Santa Cruz Biotechnology, Cat. No. sc-7884), iNOS 
(rabbit polyclonal IgG 1:1000) (Thermo scientific, Cat. 
No. PA3-030A), Notch-1 (rabbit polyclonal IgG 1:500) 
(Santa Cruz Biotechnology, Cat. No. sc-6014-R), NICD 
(Rabbit polyclonal IgG 1:1000) (Merck KGaA, Cat. No. 
07-1232), HES-1 (rabbit polyclonal IgG 1:300) (Santa 
Cruz Biotechnology, Cat. No. sc-25392) and β-actin 
(mouse monoclonal IgG 1:10000) (Sigma; Cat. No. 
A5441). Primary antibodies (Table  2) diluted in Tris-
Buffered Saline-0.1  %Tween (TBST) overnight at 4  °C 
before the membranes were incubated with the second-
ary antibodies, either with horseradish peroxidase conju-
gated anti-rabbit IgG (ThermoScientific; Cat. No. 31460), 
or anti-mouse IgG (ThermoScientific; Cat. No. 31430). 
Protein was detected by a chemiluminescence kit (GE 
Healthcare UK Limited, Bucks, UK) following the manu-
facturer’s instructions and developed on film. The band 
intensity was quantified in Image J software (National 
Institutes of Health, NIH, USA). All experiments were 
repeated at least in triplicate.
Immunofluorescence labeling of TNC1 in different 
treatments
About 5  ×  104 TNC1 astrocytes were seeded on poly-
l-lysine (Sigma, Cat. NO. P4707) pre-coated coverslips 
in a 24-well plate and left for 24 h to attach to the cov-
erslip surface before various treatments. TNC1cells were 
divided into 3 groups as described above: CM, CM + L 
and CM  +  SL. After treatment with the conditioned 
medium from the respective group for 24 h, TNC1 astro-
cytes were fixed in 4 % paraformaldehyde for 15 min at 
room temperature followed by blocking with 5  % goat 
serum for 1  h after washing with 1xPBS for 3 times at 
5  min each. Subsequently the cells were incubated with 
the respective primary antibodies (Table  2) diluted in 
1xPBS (1:100–500) at 4  °C overnight. Antibodies were 
detected with the relevant FITC/Cy3-conjugated sec-
ondary antibodies (1:200, diluted by 1× PBS) for 1 h at 
room temperature. The coverslips were then mounted 
in DAPI containing the mounting medium (Sigma, Cat. 
No. F6057) after rinsing in 1× PBS. Images were cap-
tured using a confocal microscope (FLUOVIEW FV1000; 
Olympus, Japan).
Electron microscopy
For scanning electron microscopy (SEM), TNC1 astro-
cytes from CM, CM + L and CM + SL were seeded on 
cover-slips in a 24-well plate at 2 × 104/cm2. They were 
fixed in 2 % paraformaldehyde and 3 % glutaraldehyde in 
0.1  M phosphate buffer at 4  °C for 1  h before postfixa-
tion with 1 % osmium tetroxide in PB, pH 7.4 for 30 min. 
After rinsing in 0.1  M  PB, the cell samples were dehy-
drated through an ascending series of ethanol before 
being transferred to a Bal-Tec CPD-030 critical point 
dryer (Bal-Tec AG, Balzers, Liechtenstein), using lique-
fied carbon dioxide as the transition fluid. The cover slips 
were then mounted on SEM stub. All cells were sputter-
coated with 20 nm gold in a sputter coater (Balzers SCD 
004) before examination in a scanning electron micro-
scope (FEI 650 SEM).
For transmission electron microscopy (TEM), TNC1 
cells from the respective groups were fixed in 2 % para-
formaldehyde and 3  % glutaraldehyde in PB at 4  °C for 
1 h before post-fixation with 1 % osmium tetroxide, pH 
7.4 for 1 h. After dehydration, the cells were embedded in 
resin which was allowed to polymerize at 60 °C for 24 h. 
Ultrathin sections were mounted on formvar-coated cop-
per grids and double stained with uranyl acetate and lead 
citrate. The grids were viewed in a JEOL 1010 transmis-
sion electron microscope.
Animal study
Ethics statement on use of animals
This part of the study was carried out within an appro-
priate ethical framework. While handling and use of rats, 
Table 2 Antibodies used for western blotting and immunostaining
Antibody Host Source Catalog number RRIDs
TNF‑α Rabbit polyclonal Sigma‑Aldrich, USA T8300 AB_477588
IL‑1β Rabbit polyclonal Santa Cruz Biotechnology, CA, USA sc‑7884 AB_2124476
iNOS Rabbit polyclonal Thermo scientific, CA, USA PA3‑030A AB_2152737
GFAP Mouse monoclonal Merck KGaA, Darmstadt, Germany MAB360 AB_11212597
Nestin Rabbit polyclonal Sigma‑Aldrich, USA SAB4200347
Notch‑1 Rabbit polyclonal Santa Cruz Biotechnology, CA, USA sc‑6014‑R AB_650335
NICD Rabbit polyclonal Merck KGaA, Darmstadt, Germany 07‑1232 AB_1977387
Hes‑1 Rabbit polyclonal Santa Cruz Biotechnology, CA, USA sc‑25392 AB_647996
β‑actin Mouse Monoclonal Sigma‑Aldrich, MO, USA A‑5441 AB_476744
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ethical guidelines as stated in the National Institutes of 
Health Guide for the Care and Use of Laboratory Ani-
mals were strictly adhered to. All experimental protocols 
and use of animals were approved by Kunming Medical 
University (KMU), and all efforts were made to minimize 
the number of rats used and their suffering.
Animals, surgical procedure, injection of scutellarin 
and animal groups
A total of 65 adult male Sprague–Dawley rats weighing 
250–280 g were obtained from the Experimental Animal 
Center of Kunming Medical University. All surgical pro-
cedures were carried out in the Department of Anatomy 
and Histology/Embryology, KMU. The surgical proce-
dures for middle cerebral artery occlusion (MCAO) fol-
lowed that described previously by us [43, 44]. Briefly, the 
animals were anaesthetized with an intraperitoneal injec-
tion of sodium pentobarbital (50 mg/kg). After this, a cir-
cular aperture 3 mm in diameter was burred in the right 
parietal bone with a dental drill, and the main trunk of the 
middle cerebral artery (MCA) exposed and cauterized. 
In the sham-operated rats, the same surgical procedure 
was followed but the MCA was not cauterized. All efforts 
were made to minimize the number of rats used and their 
suffering. The rats were randomly divided into sham-
operated + saline (sham), MCAO + saline (MCAO), and 
MCAO + scutellarin (100 mg/kg) (MCAO + scutellarin) 
groups (Table  3). The rats in scutellarin treated groups 
were given an intraperitoneal injection of scutellarin 
(100 mg/kg dissolved in saline Cat. No.131021,Shanghai, 
China) at 2 h before and at 12, 24, 36, 48, and 60 h after 
MCAO; rats were euthanized at 1, 3, 7, 14 and 21  days 
after MCAO.
Double immunofluorescence labeling of MCAO brain 
sections
The rats from the MCAO groups at different time-points 
after scutellarin injections (n  =  5 for each time-point) 
along with sham operated (n = 3 at each time point) and 
MCAO  +  saline injection (n  =  5 for each time-point) 
serving as the controls were used for double immunoflu-
orescence labeling. Following deep anesthesia with 6  % 
sodium pentobarbital, the rats were euthanized by per-
fusion with 2  % paraformaldehyde in 0.1  M phosphate 
buffer. The brain was removed and paraffin embed-
ded. Coronal sections of 7  μm thickness were cut on a 
microtome (Model: 2165; Leica, Bensheim, Germany). 
For blocking of nonspecific binding proteins, tissue sec-
tions were incubated in 5 % normal goat serum diluted 
in phosphate-buffered saline (PBS) for 1 h at room tem-
perature (22–24  °C). The sections were then incubated 
in a humidified chamber with the following primary 
antibodies against proinflammatory mediators: TNF-α 
(rabbit polyclonal IgG1:100) (Chemicon International, 
Temecula, CA, USA; Cat. No. AB1837P), IL-1β (rab-
bit polyclonal IgG 1:100) (Chemicon International; Cat. 
No. AB1832P) and iNOS (mouse monoclonal IgG 1:100) 
(BD Pharmingen, San Jose, CA USA; Cat. No. 610432), 
diluted with PBS overnight at 4 °C. Some sections were 
incubated in primary antibodies directed against the 
Notch signaling and its members including Notch-1 
(rabbit polyclonal IgG 1:100) (Santa Cruz Biotechnol-
ogy, Cat. No. sc-6014-R); intracellular Notch receptor 
domain, NICD (Rabbit polyclonal IgG 1:200) (Merck 
KGaA, Cat. No. 07-1232); transcription factor hairy 
and enhancer of split-1, HES-1 (rabbit polyclonal IgG 
1:100) (Santa Cruz Biotechnology, Cat. No.sc-25392) 
diluted in PBS overnight at 4  °C. Following washing in 
PBS, sections were incubated, with the respective fluo-
rescent secondary antibodies: Cy3-conjugatedsecondary 
antibody or FITC-conjugated lectin (Lycopersicon escu-
lentum), which labels both microglia and blood ves-
sel endothelial cells for 1 h at room temperature. Brain 
sections from different groups were also incubated with 
the primary antibodies against glial fibrillary acidic pro-
tein (GFAP), a specific marker for astrocytes (Merck 
KGaA, Darmstadt, Germany. Cat. No. MAB360), and 
nestin, a marker for neural stem cells (Sigma-Aldrich, 
MO, USA, Cat. No. SAB4200347). After three rinses 
with PBS, the sections were mounted with a fluorescent 
mounting medium containing 4′,6-diamidino-2-phe-
nylindole (DAPI) (Sigma, MO, USA; Cat. No. F6057). 
Colocalization was observed by confocal microscopy 
(Fluoview1000, Olympus Company Pte. Ltd., Tokyo, 
Japan). The details of the antibodies used are given in 
Table 2. The region for all staining tests in MCAO rats 
was at the border areas of the infarct epicenter of ipsilat-
eral ischemic cerebral cortex.
Statistical analysis
Statistical analysis was performed by SPSS 16.0 statisti-
cal software. The data were expressed as mean  ±  SD. 
After homogeneity test of variances, one-way Analysis 
of Variance (ANOVA) followed by multiple comparison 
of Dunnet’s test was used to determine the statistical sig-
nificance of different groups. All experiments were con-
ducted in triplicate from different cell or tissue samples. 
The difference was considered statistically significant 
when P <0.05.







n = 15 n = 25 n = 25
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Additional files
Additional file 1: (A). Scutellarin at 0.54 mM did not elicit a noticeable 
reaction of GFAP/iNOS in TNC1. (B). iNOS mRNA expression in TNC1 astro‑
cytes remained relatively unchanged at all time‑points following treat‑
ment with BM, BM + L and CM; however, when incubated with CM + L 
for various time points, TNC1 showed a remarkable increase in iNOS peak‑
ing at 24 h. (C). Confocal images showing iNOS (C1‑3) expression in TNC1 
astrocytes incubated with different medium for 24 h. Compared with cells 
incubated in BM (C1) and BM + L (C2), TNC1 astrocytes incubated with 
CM + L (C3) were hypertrophic and showed a marked increase in iNOS 
immunofluorescence. Scale bars: 20 μm. DAPI—blue.
Additional file 2: Scutellarin enhanced IL‑1β (A1, A2, A3) and iNOS 
(B1, B2, B3) expression in TNC1 via BV‑2‑conditioned medium. In TNC1 
astrocytes treated with CM, moderate expression of IL‑1β and iNOS was 
detected (A1, B1). The expression was noticeably increased in CM + L (A2, 
B2) and further enhanced upon incubation with CM + SL for 24 h (A3, 
B3) with long cytoplasmic processes with expansions projected by TNC1 
astrocytes (A3, B3). Scale bars: 20 μm.
Additional file 3: Scutellarin enhanced IL‑1β expression in astrocytes 
after MCAO. IL‑1β expression was undetected in astrocytes in the sham 
(A1‑3). Its expression (red) was noticeably induced in GFAP positive astro‑
cytes (green) at 3 and 7 days (B1‑3) after MCAO. However, the increase 
subsided at 14 days (D1‑3). In MCAO rats treated with scutellarin (C1‑3, 
E1‑3), IL‑1β expression in astrocytes was further enhanced, notably at 
14 days, when compared with the respective MCAO control groups (B1‑3, 
D1‑3). Scale bars: 50 µm. DAPI‑blue.
Additional file 4: Scutellarin enhanced iNOS expression in astrocytes 
after MCAO. iNOS expression was undetected in astrocytes in the sham 
(A1‑3). Its expression (red) was moderately induced in GFAP positive 
astrocytes (green) at 7 (B1‑3) and 14 days (D1‑3) after MCAO. In MCAO rats 
treated with scutellarin (C1‑3, E1‑3), iNOS expression in hypertrophic astro‑
cytes was further enhanced, when compared with the respective MCAO 
control groups (B1‑3, D1‑3). Scale bars: 50 µm. DAPI‑blue.
Additional file 5: Showing Notch‑1, NICD, HES‑1, Nestin, TNF‑α, IL‑1β 
and iNOS expression (red) in GFAP (green) reactive astrocytes at 21 d after 
MCAO (M) and after scutellarin treatment (M + S). Note that the expres‑
sion is diminished in MCAO but remained more intense with scutellarin 
treatment. Scale bars: 50 µm. DAPI‑blue.
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